Skip to content

ARS Pharmaceuticals, Inc.

SPRY

CIK 0001671858

← back to feed
Revenue (TTM)
$78.87M
−5.5% YoY Q1 May 2026
Net Income (TTM)
−$190.59M
−2,241.8% YoY Q1 May 2026
EPS Diluted (TTM)
−$1.94
−2,275.0% YoY Q1 May 2026
Gross Margin
100.0%
Q1 May 2026
Operating Margin
-251.2%
Q1 May 2026
Net Margin
-241.6%
Q1 May 2026
Free Cash Flow (TTM)
−$105.19M
Q1 May 2026
Cash
$24.32M
Q1 May 2026
Total Debt
$96.52M
Q1 May 2026
Shares Outstanding
99.3M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings